All In Biotech

Drug Trial Radar · NCT03847896

A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered Dose Inhaler (BDA MDI/PT027) Used 4 Times Daily in Adults and Children 4 Years of Age or Older With Asthma

A 12-week, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group, Phase III Study Evaluating the Efficacy and Safety of PT027 Compared to PT008 and PT007 Administered QID in Adults and Children 4 Years of Age or Older With Asthma

Last checked: Nov 19, 2026Latest source record: Apr 13, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,001 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,001

Actual

Start

Mar 20, 2019

Primary completion

Jul 20, 2021

Study completion Jul 20, 2021

Sponsor

Lead sponsor
Bond Avillion 2 Development LPIndustry
Sponsor type
Industry
First posted
Feb 20, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 4 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, placebo-controlled, multicenter, parallel group study to compare 2 dose levels of budesonide/albuterol BDA MDI (PT027) to its components budesonide BD MDI (PT008) and albuterol AS MDI (PT007) on improvement in lung function and asthma symptoms after 12 weeks of treatment in adult, adolescent, and child subjects with symptomatic asthma currently being treated with a short/rapid-acting β2-adrenoreceptor agonist (SABA) as needed alone or with low-dose inhaled corticosteroid (ICS) maintenance therapy plus SABA as needed.

Conditions

  • Asthma

Interventions

  • Budesonide/albuterol sulfate metered dose inhaler / BDA MDI 160/180 μg (high dose)Combination product

    Budesonide/albuterol sulfate pressurized metered dose inhaler (BDA MDI) 160/180 micrograms (μg), given as 2 inhalations of BDA MDI 80/90 μg, four times a day (QID)

  • Budesonide/albuterol sulfate metered dose inhaler / BDA MDI 80/180 μg (low dose)Combination product

    Budesonide/albuterol sulfate pressurized metered dose inhaler (BDA MDI) 80/180 micrograms (μg), given as 2 inhalations of BDA MDI 40/90 μg, four times a day (QID)

  • Budesonide metered dose inhaler / BD MDI 160 µgDrug

    Budesonide pressurized metered dose inhaler (BD MDI) 160 micrograms (μg), given as 2 inhalations of BD MDI 80 μg, four times a day (QID)

  • Albuterol sulfate metered dose inhaler / AS MDI 180 μgDrug

    Albuterol sulfate pressurized metered dose inhaler (AS MDI) 180 micrograms (μg), given as 2 inhalations of AS MDI 90 μg, four times a day (QID)

  • Placebo metered-dose inhaler / Placebo MDIOther

    Placebo pressurized metered dose inhaler (Placebo MDI), given as 2 inhalations of Placebo MDI, four times a day (QID)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Area Under the Concentration Curve From 0 to 6 Hours (AUC0-6 Hours) Over 12 WeeksTime frame: Baseline and 12 weeks
  2. Change From Baseline in Trough FEV1Time frame: Baseline and 12 weeks

Locations

129 sites in 7 countries. Site status is shown where the registry gives one.

  • Research Site

    Mobile, Alabama

  • Research Site

    Bakersfield, California

  • Research Site

    Costa Mesa, California

  • Research Site

    Encinitas, California

  • Research Site

    Huntington Beach, California

  • Research Site

    Lancaster, California

  • Research Site

    Los Angeles, California

  • Research Site

    Los Angeles, California

  • Research Site

    Newport Beach, California

  • Research Site

    Roseville, California

  • Research Site

    Sacramento, California

  • Research Site

    San Diego, California

  • Research Site

    San Jose, California

  • Research Site

    Waterbury, Connecticut

  • Research Site

    Aventura, Florida

  • Research Site

    Clearwater, Florida

  • Research Site

    Gainesville, Florida

  • Research Site

    Greenacres City, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Orlando, Florida

  • Research Site

    Oviedo, Florida

  • Research Site

    Palmetto Bay, Florida

  • Research Site

    Pembroke Pines, Florida

  • Research Site

    Pembroke Pines, Florida

  • Research Site

    Meridian, Idaho

  • Research Site

    Chicago, Illinois

  • Research Site

    Chicago, Illinois

  • Research Site

    White Marsh, Maryland

  • Research Site

    Boston, Massachusetts

  • Research Site

    North Dartmouth, Massachusetts

  • Research Site

    Farmington Hills, Michigan

  • Research Site

    Flint, Michigan

  • Research Site

    Rochester Hills, Michigan

  • Research Site

    Woodbury, Minnesota

  • Research Site

    Columbia, Missouri

  • Research Site

    Rolla, Missouri

  • Research Site

    St Louis, Missouri

Showing 40 of 129 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.